Iovance Biotherapeutics Inc. (IOVA) Interim CEO & General Counsel Owns Stock Worth $1000.0

SNOW Stock
SNOW Stock

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) finished Wednesday with a subtraction of -$0.66 to close at $10.03, a downside of -6.17 percent. An average of 2,647,560 shares of common stock have been traded in the last five days. There was a fall of -$1.04 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 2,206,800 shares traded, while the 50-day average volume stands at 2,356,206.

IOVA stock has decreased by -14.78% in the last month. The company shares reached their 1-month lowest point of $9.92 on 09/07/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $6.18 and a high of $27.96 in 52 weeks. It has reached a new high 1 time so far this year and lost -47.46% or -$9.06 in price. In spite of this, the price is down -64.13% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Valuation Metrics

Iovance Biotherapeutics Inc. (IOVA) stock’s beta is 0.47. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.33.

Financial Health

The quick ratio of Iovance Biotherapeutics Inc. for the three months ended June 29 was 6.70, and the current ratio was 6.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Iovance Biotherapeutics Inc.’s return on assets was -51.60%.

Earnings Surprise

For the three-month period that ended June 29, Iovance Biotherapeutics Inc. had $316.38 million in cash and short-term investments compared to $1.0 million in total debt. The company posted a net income of -$99.35 million in the quarter, while revenues of -$91.61 million were grew 18.12%. The analyst consensus anticipated Iovance Biotherapeutics Inc.’s latest quarter earnings to come in at -$0.61 per share, but it turned out to be -$0.63, a -3.30% surprise. Shareholders own equity worth $157.8 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Iovance Biotherapeutics Inc. (IOVA) price momentum. RSI 9-day as of the close on 21 September was 35.94%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.59%.

As of today, IOVA’s price is $10.81 -9.39% or -$1.04 from its 5-day moving average. IOVA is currently trading -14.57% lower than its 20-day SMA and -35.66% lower than its 100-day SMA. However, the stock’s current price level is -17.45% below the SMA50 and -39.40% below the SMA200.

The stochastic %K and %D were 27.21% and 43.08%, respectively, and the average true range (ATR) was 0.68. With the 14-day stochastic at 5.61% and the average true range at 0.69, the RSI (14) stands at 39.31%. The stock has reached -0.54 on the 9-day MACD Oscillator while the 14-day reading was at -0.47.


Please enter your comment!
Please enter your name here